


IN THE CLAIMS

Please amend claims 1, 2, 3, 25 and 27-28 as follows:

1. (Thrice Amended) A compound of the formula

(I):



(I)

or a pharmaceutically acceptable salt thereof; wherein:

A is tetrahydrofurodihydrofuranyl-O-C(O)-, wherein tetrahydrofurodihydrofuranyl is optionally substituted with one or more substituents independently selected from oxo, -OR<sup>2</sup>, SR<sup>2</sup>, -R<sup>2</sup>, -N(R<sup>2</sup>)(R<sup>2</sup>), -R<sup>2</sup>-OH, -CN, -CO<sub>2</sub>R<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, -S(O)<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sup>2</sup>, -N(R<sup>2</sup>)-C(O)O-R<sup>2</sup>, -C(O)-R<sup>2</sup>, -S(O)<sub>n</sub>-R<sup>2</sup>, -OCF<sub>3</sub>, -S(O)<sub>n</sub>-Q, methylenedioxy, -N(R<sup>2</sup>)-S(O)<sub>2</sub>(R<sup>2</sup>), halo, -CF<sub>3</sub>, -NO<sub>2</sub>, Q, -OQ, -OR<sup>7</sup>, -SR<sup>7</sup>, -R<sup>7</sup>, -N(R<sup>2</sup>)(R<sup>7</sup>) or -N(R<sup>7</sup>)<sub>2</sub>;

each Ht is independently selected from C<sub>3</sub>-C<sub>7</sub> cycloalkyl; C<sub>5</sub>-C<sub>7</sub> cycloalkenyl; C<sub>6</sub>-C<sub>14</sub> aryl; or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, N(R<sup>2</sup>), O, S and S(O)<sub>n</sub>; wherein said aryl or said heterocycle is optionally fused to Q; and wherein any member of said Ht is optionally substituted with one or more substituents independently selected from oxo, -OR<sup>2</sup>, SR<sup>2</sup>, -R<sup>2</sup>, -N(R<sup>2</sup>)(R<sup>2</sup>), -R<sup>2</sup>-OH, -CN, -CO<sub>2</sub>R<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, -S(O)<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sup>2</sup>, -N(R<sup>2</sup>)-C(O)O-R<sup>2</sup>, -C(O)-R<sup>2</sup>, -S(O)<sub>n</sub>-R<sup>2</sup>, -OCF<sub>3</sub>, -S(O)<sub>n</sub>-Q, methylenedioxy, -N(R<sup>2</sup>)-S(O)<sub>2</sub>(R<sup>2</sup>), halo, -CF<sub>3</sub>, -NO<sub>2</sub>, Q, -OQ, -OR<sup>7</sup>, -SR<sup>7</sup>, -R<sup>7</sup>, -N(R<sup>2</sup>)(R<sup>7</sup>) or -N(R<sup>7</sup>)<sub>2</sub>;

C2  
central

each  $R^2$  is independently selected from H, or  $C_1$ - $C_4$  alkyl optionally substituted with a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from O, N, S,  $S(O)_n$  or  $N(R^{33})$ ; wherein any of said ring systems or  $N(R^{33})$  is optionally substituted with 1 to 4 substituents independently selected from  $-X'-Y'$ ,  $-O$ -arylalkyl,  $-S$ -arylalkyl,  $-N(Y')_2$ ,  $-N(H)$ -arylalkyl,  $-N(C_1-C_4$  alkyl)-arylalkyl, oxo,  $-O-(C_1-C_4$  alkyl), OH,  $C_1-C_4$  alkyl,  $-SO_2H$ ,  $-SO_2-(C_1-C_4$  alkyl),  $-SO_2-NH_2$ ,  $-SO_2-NH(C_1-C_4$  alkyl),  $-SO_2-N(C_1-C_4$  alkyl) $_2$ ,  $-NH_2$ ,  $-NH(C_1-C_4$  alkyl),  $-N(C_1-C_4$  alkyl) $_2$ ,  $-NH-C(O)H$ ,  $-N(C_1-C_4$  alkyl)- $C(O)H$ ,  $-NH-C(O)-C_1-C_4$  alkyl,  $-C_1-C_4$  alkyl-OH,  $-OH$ ,  $-CN$ ,  $-C(O)OH$ ,  $-C(O)O-C_1-C_4$  alkyl,  $-C(O)-NH_2$ ,  $-C(O)-NH(C_1-C_4$  alkyl),  $-C(O)-N(C_1-C_4$  alkyl) $_2$ , halo or  $-CF_3$ ;

$X'$  is  $-O-$ ,  $-S-$ ,  $-NH-$ ,  $-NHC(O)-$ ,  $-NHC(O)O-$ ,  $-NHSO_2-$ , or  $-N-(C_1-C_4)$ alkyl-;

$Y'$  is  $C_1$ - $C_{15}$  alkyl,  $C_2$ - $C_{15}$  alkenyl or alkynyl, wherein one to five carbon atoms in  $Y'$  are optionally substituted with  $C_3$ - $C_7$  cycloalkyl or  $C_5$ - $C_6$  cycloalkenyl,  $C_6$ - $C_{14}$  aryl or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, NH, O, S and  $S(O)_n$ ;

each  $R^3$  is independently selected from H, Ht,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl or  $C_5$ - $C_6$  cycloalkenyl; wherein any member of said  $R^3$ , except H, is optionally substituted with one or more substituents selected from  $-OR^2$ ,  $-C(O)-N(R^2)_2$ ,  $-S(O)_n-N(R^2)_2$ ,  $-N(R^2)_2$ ,  $-N(R^2)-C(O)O(R^2)$ ,  $-N(R^2)-C(O)N(R^2)_2$ ,  $-N(R^2)-C(O)-R^2$ , Ht,  $-CN$ ,  $-SR^2$ ,  $-C(O)OR^2$ , or  $N(R^2)-C(O)-R^2$ ;

each  $R^{33}$  is selected from H,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl or  $C_5$ - $C_6$  cycloalkenyl,  $C_6$ - $C_{14}$  aryl or a 5-7 membered saturated or

unsaturated heterocycle, containing one or more heteroatoms selected from N, NH, O, S and S(O)<sub>n</sub>;

each n is independently 1 or 2;

G is selected from H or C<sub>1</sub>-C<sub>4</sub> alkyl;

x in (G)<sub>x</sub> is 1;

D is C<sub>1</sub>-C<sub>6</sub> alkyl substituted with Q, wherein said alkyl is optionally substituted with one or more groups selected from C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -R<sup>3</sup>, -O-Q or Q;

each Q is independently selected from a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; wherein Q contains one substituent selected from -OR<sup>8</sup>, -OR<sup>8</sup>, -O-arylalkyl, -SR<sup>8</sup>, -S-arylalkyl, -N(R<sup>2</sup>)R<sup>8</sup>, -N(R<sup>2</sup>)-arylalkyl and may be optionally substituted with one or more additional substituents independently selected from oxo, -OR<sup>8</sup>, -O-arylalkyl, -SR<sup>8</sup>, -S-arylalkyl, -N(R<sup>2</sup>)R<sup>8</sup>, -N(R<sup>2</sup>)-arylalkyl, -OR<sup>2</sup>, -R<sup>2</sup>, -SO<sub>2</sub>R<sup>2</sup>, -SO<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sup>2</sup>, -OH, (C<sub>1</sub>-C<sub>4</sub>)-OH, -CN, -CO<sub>2</sub>R<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, halo or -CF<sub>3</sub>;

each R<sup>8</sup> is independently selected from Ht, -C<sub>1</sub>-C<sub>15</sub> branched or straight chain alkyl, alkenyl or alkynyl wherein one to five carbon atoms in said alkyl, alkenyl or alkynyl are independently replaced by W, or wherein one to five carbon atoms in said alkyl, alkenyl or alkynyl are substituted with Ht; and wherein R<sup>8</sup> is additionally and optionally substituted with one or more groups independently selected from -OH; -S(C<sub>1</sub>-C<sub>6</sub> alkyl); -CN; -CF<sub>3</sub>; -N(R<sup>2</sup>)<sub>2</sub>; halo; -C<sub>1</sub>-C<sub>4</sub>-alkyl; -C<sub>1</sub>-C<sub>4</sub>-alkoxy; -Ht; -O-Ht; -NR<sup>2</sup>-CO-N(R<sup>2</sup>)<sub>2</sub>; -CO-N(R<sup>2</sup>)<sub>2</sub>; -R<sup>1</sup>-C<sub>2</sub>-C<sub>6</sub> alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy, C<sub>1</sub>-C<sub>4</sub> alkoxy, -Ht; -O-Ht, -NR<sup>2</sup>-CO-N(R<sup>2</sup>)<sub>2</sub> or -CO-N(R<sup>2</sup>)<sub>2</sub>; or R<sup>7</sup>;


wherein W is -O-, -NR<sup>2</sup>-, -S-, -C(O)-, -C(S)-, -C(=NR<sup>2</sup>)-, -S(O)<sub>2</sub>-, -NR<sup>2</sup>-S(O)<sub>2</sub>-, -S(O)<sub>2</sub>-NR<sup>2</sup>-, -NR<sup>2</sup>-C(O)O-, -O-C(O)NR<sup>2</sup>-, -NR<sup>2</sup>-C(O)NR<sup>2</sup>-, -NR<sup>2</sup>-C(S)NR<sup>2</sup>-, -CONR<sup>2</sup>, -NR<sup>2</sup>C(O)-,

-C(S)NR<sup>2</sup>, -NR<sup>2</sup>C(S)-, -NR<sup>2</sup>-C(=N-CN)-NR<sup>2</sup>-, -NR<sup>2</sup>C(=N-CN)O- or -C(O)O-;

D' is selected from C<sub>1</sub>-C<sub>15</sub> alkyl, C<sub>1</sub>-C<sub>15</sub> alkoxy, C<sub>2</sub>-C<sub>15</sub> alkenyl, C<sub>2</sub>-C<sub>15</sub> alkenyloxy, C<sub>2</sub>-C<sub>15</sub> alkynyl, or C<sub>2</sub>-C<sub>15</sub> alkynyloxy, wherein D' optionally comprises one or more substituents independently selected from Ht, oxo, halo, -CF<sub>3</sub>, -OCF<sub>3</sub>, -NO<sub>2</sub>, azido, -SH, -SR<sup>3</sup>, -N(R<sup>3</sup>)-N(R<sup>3</sup>)<sub>2</sub>, -O-N(R<sup>3</sup>)<sub>2</sub>, -(R<sup>3</sup>)N-O-(R<sup>3</sup>), -N(R<sup>3</sup>)<sub>2</sub>, -CN, -CO<sub>2</sub>R<sup>3</sup>, -C(O)-N(R<sup>3</sup>)<sub>2</sub>, -S(O)<sub>n</sub>-N(R<sup>3</sup>)<sub>2</sub>, -N(R<sup>3</sup>)-C(O)-R<sup>3</sup>, -N(R<sup>3</sup>)-C(O)-N(R<sup>3</sup>)<sub>2</sub>, -C(O)-R<sup>3</sup>, -S(O)<sub>n</sub>-R<sup>3</sup>, -N(R<sup>3</sup>)-S(O)<sub>n</sub>(R<sup>3</sup>), -N(R<sup>3</sup>)-S(O)<sub>n</sub>-N(R<sup>3</sup>)<sub>2</sub>, -S-NR<sup>3</sup>-C(O)R<sup>3</sup>, -C(S)N(R<sup>3</sup>)<sub>2</sub>, -C(S)R<sup>3</sup>, -NR<sup>3</sup>-C(O)OR<sup>3</sup>, -O-C(O)OR<sup>3</sup>, -O-C(O)N(R<sup>3</sup>)<sub>2</sub>, -NR<sup>3</sup>-C(S)R<sup>3</sup>, =N-OH, =N-OR<sup>3</sup>, =N-N(R<sup>3</sup>)<sub>2</sub>, =NR<sup>3</sup>, =NNR<sup>3</sup>C(O)N(R<sup>3</sup>)<sub>2</sub>, =NNR<sup>3</sup>C(O)OR<sup>3</sup>, =NNR<sup>3</sup>S(O)<sub>n</sub>-N(R<sup>3</sup>)<sub>2</sub>, -NR<sup>3</sup>-C(S)OR<sup>3</sup>, -NR<sup>3</sup>-C(S)N(R<sup>3</sup>)<sub>2</sub>, -NR<sup>3</sup>-C[=N(R<sup>3</sup>)]-N(R<sup>3</sup>)<sub>2</sub>, -N(R<sup>3</sup>)-C[=N-NO<sub>2</sub>]-N(R<sup>3</sup>)<sub>2</sub>, -N(R<sup>3</sup>)-C[=N-NO<sub>2</sub>]-OR<sup>3</sup>, -OC(O)R<sup>3</sup>, -OC(S)R<sup>3</sup>, -OC(O)N(R<sup>3</sup>)<sub>2</sub>, -C(O)N(R<sup>3</sup>)-N(R<sup>3</sup>)<sub>2</sub>, -N(R<sup>3</sup>)-N(R<sup>3</sup>)C(O)R<sup>3</sup>, -N(R<sup>3</sup>)-OC(O)R<sup>3</sup>, -N(R<sup>3</sup>)-OC(O)R<sup>3</sup>, -OC(S)N(R<sup>3</sup>)<sub>2</sub>, -OC(S)N(R<sup>3</sup>)(R<sup>3</sup>), or -PO<sub>3</sub>-R<sup>3</sup>;

E is benzothiazolyl optionally substituted with one or more substituents independently selected from oxo, -OR<sup>2</sup>, SR<sup>2</sup>, -R<sup>2</sup>, -N(R<sup>2</sup>)(R<sup>2</sup>), -R<sup>2</sup>-OH, -CN, -CO<sub>2</sub>R<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, -S(O)<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sup>2</sup>, -N(R<sup>2</sup>)-C(O)O-R<sup>2</sup>, -C(O)-R<sup>2</sup>, -S(O)<sub>n</sub>-R<sup>2</sup>, -OCF<sub>3</sub>, -S(O)<sub>n</sub>-Q, methylenedioxy, -N(R<sup>2</sup>)-S(O)<sub>2</sub>(R<sup>2</sup>), halo, -CF<sub>3</sub>, -NO<sub>2</sub>, Q, -OQ, -OR<sup>7</sup>, -SR<sup>7</sup>, -R<sup>7</sup>, -N(R<sup>2</sup>)(R<sup>7</sup>) or -N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>7</sup> is independently selected from hydrogen,



wherein each M is independently selected from H, Li, Na, K, Mg, Ca, Ba, -N(R<sup>2</sup>)<sub>4</sub>, C<sub>1</sub>-C<sub>12</sub>-alkyl, C<sub>2</sub>-C<sub>12</sub>-alkenyl, or -R<sup>6</sup>; wherein 1 to 4 -CH<sub>2</sub> radicals of the alkyl or alkenyl group, other than the -CH<sub>2</sub> that is bound

C2  
to Z, is optionally replaced by a heteroatom group selected from O, S, S(O), S(O<sub>2</sub>), or N(R<sup>2</sup>); and wherein any hydrogen in said alkyl, alkenyl or R<sup>6</sup> is optionally replaced with a substituent selected from oxo, -C<sub>1</sub>-C<sub>4</sub> alkyl, -N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)<sub>3</sub>, -OH, -O-(C<sub>1</sub>-C<sub>4</sub> alkyl), -CN, -C(O)OR<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, S(O)<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sub>2</sub>, C(O)R<sup>2</sup>, -S(O)<sub>n</sub>-R<sup>2</sup>, -OCF<sub>3</sub>, -S(O)<sub>n</sub>-R<sup>6</sup>, -N(R<sup>2</sup>)-S(O)<sub>2</sub>(R<sup>2</sup>), halo, -CF<sub>3</sub>, or -NO<sub>2</sub>;

M' is H, C<sub>1</sub>-C<sub>12</sub>-alkyl, C<sub>2</sub>-C<sub>12</sub>-alkenyl, or -R<sup>6</sup>; wherein 1 to 4 -CH<sub>2</sub> radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected from O, S, S(O), S(O<sub>2</sub>), or N(R<sup>2</sup>); and wherein any hydrogen in said alkyl, alkenyl or R<sup>6</sup> is optionally replaced with a substituent selected from oxo, -OR<sup>2</sup>, -C<sub>1</sub>-C<sub>4</sub> alkyl, -N(R<sup>2</sup>)<sub>2</sub>, N(R<sup>2</sup>)<sub>3</sub>, -OH, -O-(C<sub>1</sub>-C<sub>4</sub> alkyl), -CN, -C(O)OR<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, -S(O)<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sub>2</sub>, -C(O)R<sup>2</sup>, -S(O)<sub>n</sub>-R<sup>2</sup>, -OCF<sub>3</sub>, -S(O)<sub>n</sub>-R<sup>6</sup>, -N(R<sup>2</sup>)-S(O)<sub>2</sub>(R<sup>2</sup>), halo, -CF<sub>3</sub>, or -NO<sub>2</sub>;

x, when associated with R<sup>7</sup>, is 0 or 1;

Z is O, S, N(R<sup>2</sup>)<sub>2</sub>, or, when M is not present, H;

Y is P or S;

X is O or S;

R<sup>9</sup> is C(R<sup>2</sup>)<sub>2</sub>, O or N(R<sup>2</sup>); wherein when Y is S, Z is not S; and

R<sup>6</sup> is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered saturated, partially saturated or unsaturated bicyclic ring system; wherein any of said heterocyclic ring systems contains one or more heteroatoms selected from O, N, S, S(O)<sub>n</sub> or N(R<sup>2</sup>); and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from -OH, -C<sub>1</sub>-C<sub>4</sub> alkyl, -O-(C<sub>1</sub>-C<sub>4</sub> alkyl) or -O-C(O)-(C<sub>1</sub>-C<sub>4</sub> alkyl).

2. (Amended) The compound according to claim 1, wherein R<sup>8</sup> is -C<sub>1</sub>-C<sub>4</sub>-branched or straight chain alkyl,

02  
amended

wherein one to two carbon atoms in said alkyl are independently replaced by W, wherein  $R^8$  is additionally and optionally substituted with one or more groups independently selected from -OH; -C<sub>1</sub>-C<sub>4</sub>-alkoxy; -Ht; -O-Ht; -NR<sup>2</sup>-CO-N(R<sup>2</sup>)<sub>2</sub>; -CO-N(R<sup>2</sup>)<sub>2</sub>; -R<sup>1</sup>-C<sub>2</sub>-C<sub>6</sub> alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy, C<sub>1</sub>-C<sub>4</sub> alkoxy, -Ht; -O-Ht, -NR<sup>2</sup>-CO-N(R<sup>2</sup>)<sub>2</sub> or -CO-N(R<sup>2</sup>)<sub>2</sub>; or R<sup>7</sup>; and

wherein W is -O-, -NR<sup>2</sup>-, -NR<sup>2</sup>-S(O)<sub>2</sub>-, -NR<sup>2</sup>-C(O)O-, -O-C(O)NR<sup>2</sup>-, -NR<sup>2</sup>-C(O)NR<sup>2</sup>-, -NR<sup>2</sup>-C(S)NR<sup>2</sup>-, -NR<sup>2</sup>C(O)-, -C(=NR<sup>2</sup>)-, -C(O)NR<sup>2</sup>-, -NR<sup>2</sup>-C(=N-CN)-NR<sup>2</sup>-, -NR<sup>2</sup>C(=N-CN)O- or -C(O)O-.

3. (Amended) The compound according to claim 1, wherein  $R^8$  is a -C<sub>1</sub>-C<sub>4</sub>-branched or straight alkyl chain, wherein one to two carbon atoms are substituted with Ht;

wherein Ht is C<sub>6-14</sub> aryl or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, N(R<sup>2</sup>), O, S and S(O)<sub>n</sub>, wherein any member of Ht is optionally substituted with one or more substituents independently selected from oxo, -OR<sup>2</sup>, SR<sup>2</sup>, -R<sup>2</sup>, -N(R<sup>2</sup>)(R<sup>2</sup>), -R<sup>2</sup>-OH, -CN, -CO<sub>2</sub>R<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, -S(O)<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sup>2</sup>, -N(R<sup>2</sup>)-C(O)O-R<sup>2</sup>, -C(O)-R<sup>2</sup>, -S(O)<sub>n</sub>-R<sup>2</sup>, -OCF<sub>3</sub>, -S(O)<sub>n</sub>-Q, methylenedioxy, -N(R<sup>2</sup>)-S(O)<sub>2</sub>(R<sup>2</sup>), halo, -CF<sub>3</sub>, -NO<sub>2</sub>, Q, -OQ, -OR<sup>7</sup>, -SR<sup>7</sup>, -R<sup>7</sup>, -N(R<sup>2</sup>)(R<sup>7</sup>) or -N(R<sup>7</sup>)<sub>2</sub>.

03

25. (Amended) The method according to claim 23 or 24, comprising the additional step of administering to said patient an additional therapeutic agent selected from (1 alpha, 2 beta, 3 alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine [(-)BHCG, SQ-34514]; oxetanocin-G (3,4-bis-(hydroxymethyl)-2-oxetanosyl]guanine); acyclic nucleosides, acyclovir (9-[(2-hydroxyethoxy)methyl]guanine), valaciclovir (L-valine 2-(guanin-9-

C3  
center

ylmethoxy)ethyl ester), famciclovir (diacetyl-6-deoxy-9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine), ganciclovir (9-[[2-hydroxy-1-(hydroxymethyl)ethoxy] methyl] guanine), penciclovir (9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine); acyclic nucleoside phosphonates, (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC); ribonucleotide reductase inhibitors, 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl] thiocarbonohydrazone, 3'-azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, 2',3'-didehydrothymidine; other aspartyl protease inhibitors, indinavir (4-hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyll]hexanedi- amide), ritonavir (2,4,7,12-tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-,5-thiazolylmethyl ester, [5S-(5R\*,8R\*,10R\*,11R\*)], nelfinavir (3S-(3R\*,4aR\*,8aR\*,2'S\*,3'S\*)]-2-[2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)-pentyl]-3-(N-(tert-butyl)-carboxy-amide)-decahydroisoquinoline-methanesulfonic acid), [3S-[3R\*(1R\*, 2S\*)]]-[3[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-tetrahydro-3-furanyl ester (amprenavir); oxathiolane nucleoside analogues, (-)-cis-1-(2-hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine (lamivudine), cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC); 3'-deoxy-3'-fluorothymidine; 5-chloro-2',3'-dideoxy-3'-fluorouridine; (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ribavirin; 9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G); tat inhibitors, 7-chloro-5-(2-pyrryl)-3H-1,4-benzodiazepin-2-(H)one (Ro5-3335), 7-chloro-1,3-

C3  
CMT

dihydro-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine (Ro24-7429); interferons,  $\alpha$ -interferon; renal excretion inhibitors, probenecid; nucleoside transport inhibitors, dipyridamole; pentoxifylline; N-acetylcysteine (NAC); Procysteine;  $\alpha$ -trichosanthin; phosphonoformic acid; immunomodulators, interleukin II, thymosin; granulocyte macrophage colony stimulating factors; erythropoetin; soluble CD<sub>4</sub> and genetically engineered derivatives thereof; non-nucleoside reverse transcriptase inhibitors (NNRTIs), nevirapine (BI-RG-587; N11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido [3,2-b:2',3'-e] [1,4] diazepin-6-one), loviride ( $\alpha$ -APA; (+)-2,6-dichloro-alpha-[(2-acetyl-5-methylphenyl)amino]benzamide), delavirdine (BHAP; 1-(5-methanesulphonamido)-1H-indol-2-yl-carbonyl)-4-[3-(isopropylamino)-2-pyridinyl] piperazine); phosphonoformic acid; 1,4-dihydro-2H-3,1-benzoxazin-2-ones NNRTIs, (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); quinoxaline NNRTIs, or isopropyl (2S)-7-fluoro-3,4-dihydro-2-ethyl-3-oxo-1(2H)-quinoxalinecarboxylate (HBY1293), wherein said additional agent is administered to said patient as either a separate dosage form or as a single dosage form together with said compound.

---

C4

27. (Amended) The method according to claim 26, comprising the additional step of administering to said patient an additional therapeutic agent selected from (1 alpha, 2 beta, 3 alpha)-9-[2,3-bis(hydroxymethyl) cyclobutyl]guanine [(-)BHCG, SQ-34514]; oxetanocin-G (3,4-bis-(hydroxymethyl)-2-oxetanosyl]guanine); acyclic nucleosides, acyclovir (9-[(2-hydroxyethoxy)methyl] guanine), valaciclovir (L-valine 2-(guanin-9-ylmethoxy)ethyl ester), famciclovir (diacetyl-6-deoxy-9-



(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine), ganciclovir  
 (9-[[2-hydroxy-1-(hydroxymethyl)ethoxy] methyl] guanine),  
 penciclovir (9-(4-hydroxy-3-hydroxymethyl-but-1-yl)  
 guanine); acyclic nucleoside phosphonates, (S)-1-(3-  
 hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC);  
 ribonucleotide reductase inhibitors, 2-acetylpyridine 5-  
 [(2-chloroanilino)thiocarbonyl] thiocarbonohydrazone,  
 3'-azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides  
 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-  
 dideoxyinosine, 2',3'-didehydrothymidine; other aspartyl  
 protease inhibitors, indinavir (4-hydroxy-N-(2-hydroxy-  
 2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-  
 phenylmethyl-5-[4-(3-pyridylmethyl)-1-  
 piperziny]hexanediamide), ritonavir (2,4,7,12 -  
 tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-  
 methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-  
 8,11-bis(phenylmethyl)-,5-thiazolylmethyl ester, [5S-  
 (5R\*,8R\*,10R\*,11R\*)], nelfinavir (3S-  
 (3R\*,4aR\*,8aR\*,2'S\*,3'S\*))]-2-[2'-hydroxy-3'-  
 phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-  
 hydroxyphenyl)-pentyl]-3-(N-(tert-butyl)-carboxy-amide)-  
 decahydroisoquinoline-methanesulfonic acid), [3S-  
 [3R\*(1R\*, 2S\*)]]-3[[[(4-aminophenyl)sulfonyl](2-  
 methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-  
 tetrahydro-3-furanyl ester (amprenavir); oxathiolane  
 nucleoside analogues, (-)-cis-1-(2-hydroxymethyl)-1,3-  
 oxathiolane 5-yl)-cytosine (lamivudine), cis-1-(2-  
 (hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine  
 (FTC); 3'-deoxy-3'-fluorothymidine; 5-chloro-2',3'-  
 dideoxy-3'-fluorouridine; (-)-cis-4-[2-amino-6-  
 (cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-  
 methanol; ribavirin; 9-[4-hydroxy-2-(hydroxymethyl)but-1-  
 yl]-guanine (H2G); tat inhibitors, 7-chloro-5-(2-pyrryl)-  
 3H-1,4-benzodiazepin-2-(H)one (Ro5-3335), 7-chloro-1,3-  
 dihydro-5-(1H-pyrrol-2yl)-3H-1,4-benzodiazepin-2-amine

CF  
Anty

(Ro24-7429); interferons,  $\alpha$ -interferon; renal excretion inhibitors, probenecid; nucleoside transport inhibitors, dipyridamole; pentoxifylline; N-acetylcysteine (NAC); Procysteine;  $\alpha$ -trichosanthin; phosphonoformic acid; immunomodulators, interleukin II or thymosin; granulocyte macrophage colony stimulating factors; erythropoietin; soluble CD<sub>4</sub> and genetically engineered derivatives thereof; non-nucleoside reverse transcriptase inhibitors (NNRTIs), nevirapine (BI-RG-587; N11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido [3,2-b:2',3'-e] [1,4] diazepin-6-one), loviride ( $\alpha$ -APA; (+)-2,6-dichloro-alpha-[(2-acetyl-5-methylphenyl)amino]benzamide), delavirdine (BHAP; 1-(5-methanesulphonamido)-1H-indol-2-yl-carbonyl)-4-[3-(isopropylamino)-2-pyridinyl] piperazine); phosphonoformic acid; 1,4-dihydro-2H-3,1-benzoxazin-2-ones NNRTIs, (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); quinoxaline NNRTIs, or isopropyl (2S)-7-fluoro-3,4-dihydro-2-ethyl-3-oxo-1(2H)-quinoxalinecarboxylate (HBY1293), wherein said additional agent is administered to said patient as either a separate dosage form or as a single dosage form together with said compound.

28. (Amended) The composition according to claim 21, wherein said acyclic nucleosides are acyclovir (9-[(2-hydroxyethoxy)methyl] guanine), valaciclovir (L-valine 2-(guanin-9-ylmethoxy)ethyl ester), famciclovir (diacetyl-6-deoxy-9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine), ganciclovir (9-[[2-hydroxy-1-(hydroxymethyl)ethoxy] methyl] guanine) or penciclovir (9-(4-hydroxy-3-hydroxymethyl-but-1-yl) guanine); said acyclic nucleoside phosphonates are (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC); said

ribonucleotide reductase inhibitors are 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl] thiocarbonohydrazone, or 3'-azido-3'-deoxythymidine; said other 2',3'-dideoxynucleosides are 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, or 2',3'-didehydrothymidine; said other aspartyl protease inhibitors are indinavir (4-hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyllhexanedi- amide), ritonavir (2,4,7,12-tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-,5-thiazolylmethyl ester, [5S-(5R\*,8R\*10R\*,11R\*)], nelfinavir (3S-(3R\*,4aR\*,8aR\*,2'S\*,3'S\*)]-2-[2'hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)-pentyl]-3-(N-(tert-butyl)-carboxy-amide)-decahydroisoquinoline-methanesulfonic acid), or [3S-[3R\*(1R\*, 2S\*)]]-[3[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-tetrahydro-3-furanyl ester (amprenavir); said oxathiolane nucleoside analogues are (-)-cis-1-(2-hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine (lamivudine) or cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC); said tat inhibitors are 7-chloro-5-(2-pyrrolyl)-3H-1,4-benzodiazepin-2-(H)one (Ro5-3335) or 7-chloro-1,3-dihydro-5-(1H-pyrrol-2yl)-3H-1,4-benzodiazepin-2-amine (Ro24-7429); said interferons are  $\alpha$ -interferon; said renal excretion inhibitors are probenecid; said nucleoside transport inhibitors are dipyridamole; said immunomodulators are interleukin II or thymosin; said non-nucleoside reverse transcriptase inhibitors (NNRTIs) are nevirapine (BI-RG-587; N11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido [3,2-b:2',3'-e][1,4] diazepin-6-

one), loviride ( $\alpha$ -APA; (+-)-2,6-dichloro- $\alpha$ -[(2-acetyl-5-methylphenyl)amino]benzamide) or delavirdine (BHAP; 1-(5-methanesulphonamido)-1H-indol-2-yl-carbonyl)-4-[3-(isopropylamino)-2-pyridinyl] piperazine); said 1,4-dihydro-2H-3,1-benzoxazin-2-ones NNRTIs are (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); or said quinoxaline NNRTIs are isopropyl (2S)-7-fluoro-3,4-dihydro-2-ethyl-3-oxo-1(2H)-quinoxalinecarboxylate (HBY1293).

---